Celltrion and Yonsei University Health System will develop new biopharmaceuticals

| By | Drug Development, Innovative Medicines
0
181

Celltrion (South Korea) signed an agreement with Yonsei University Health System on the joint development and license-in of Fc-Saxatilin, a candidate drug for ischemic strokes in a bid to develop new biopharmaceuticals for cerebrovascular diseases.

Under the agreement, Celltrion and Yonsei University Health System will conduct joint development for the optimization of the Fc-Saxatilin molecule, after which Celltrion will have an option for the exclusive worldwide license to conduct clinical trials, to obtain approvals, and to commercialize the drug.

Fc-Saxatilin, which is a new molecule developed by Professor Ji Hoe Heo-led team of the Severance Integrative Research Institute for Cerebral & Cardiovascular Diseases of Yonsei University is expected to have superior efficacy and safety to existing treatments in terms of thrombolytic effect and lower side effects (cerebral hemorrhage) in patients with ischemic stroke (cerebral infarction) caused by the blocking of cerebral blood vessel.

Headquartered in Incheon, South Korea, Celltrion is a leading biopharmaceutical company, specializing in research, development and manufacture of biosimilar and innovative drugs. Celltrion strives to provide more affordable biosimilar mAbs to patients who previously had limited access to advanced therapeutics. Celltrion received FDA and EC’s approval for INFLECTRA® and Remsima®, respectively, which is the world’s first mAb biosimilar to receive approval from a regulatory agency in a developed country.

Yonsei University Health System (YUHS) was founded in 1885 as the first modern medical institution in South Korea. YUHS includes 3 colleges (Medicine, Dentistry, Nursing), graduate schools, and 4 hospitals named as Severance hospitals. Based on more than 130 years of experience in medicine and scientific manpower in research fields, YUHS strives to achieve its goal of becoming the medical research hub through close cooperation.

SOURCE: celltrion
SHARE
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.